Abstract
7TM receptors constitute one of the largest superfamilies of proteins in the human genome. They are involved in a large number of physiological and pathological processes and thus represent major and important drug targets for the pharmaceutical industry. Although the majority have been deorphanized, many remain orphan and these orphan receptors constitute a large pool of potential drug targets. This review focuses on one of these orphan targets, the Epstein-Barr Virus – induced receptor 2, EBI2 (or GPR183), together with two structurally related receptors, GPR17 and GPR18. The pharmacology and “druggability” of these three receptors are reviewed through a thorough description of their structural and functional properties and in vivo biology together with a status of currently available ligands for these receptors.
Keywords: GPCR, activation mechanism, 7TM receptors, EBI2, GPR18, GPR17, constitutive activity, deorphanization, orphan receptors, druggability, chromosomal region 13q32.3, chemogenomic analysis, pertussis toxin, –, dependent manner, phosphatidylinositol turnover, posttransplant lymphoproliferative diseases
Current Topics in Medicinal Chemistry
Title: EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Volume: 11 Issue: 6
Author(s): Kristine Norregaard, Tau Benned-Jensen and Mette Marie Rosenkilde
Affiliation:
Keywords: GPCR, activation mechanism, 7TM receptors, EBI2, GPR18, GPR17, constitutive activity, deorphanization, orphan receptors, druggability, chromosomal region 13q32.3, chemogenomic analysis, pertussis toxin, –, dependent manner, phosphatidylinositol turnover, posttransplant lymphoproliferative diseases
Abstract: 7TM receptors constitute one of the largest superfamilies of proteins in the human genome. They are involved in a large number of physiological and pathological processes and thus represent major and important drug targets for the pharmaceutical industry. Although the majority have been deorphanized, many remain orphan and these orphan receptors constitute a large pool of potential drug targets. This review focuses on one of these orphan targets, the Epstein-Barr Virus – induced receptor 2, EBI2 (or GPR183), together with two structurally related receptors, GPR17 and GPR18. The pharmacology and “druggability” of these three receptors are reviewed through a thorough description of their structural and functional properties and in vivo biology together with a status of currently available ligands for these receptors.
Export Options
About this article
Cite this article as:
Norregaard Kristine, Benned-Jensen Tau and Marie Rosenkilde Mette, EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors, Current Topics in Medicinal Chemistry 2011; 11 (6) . https://dx.doi.org/10.2174/1568026611109060618
DOI https://dx.doi.org/10.2174/1568026611109060618 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Application of Lentiviral Vectors – Concepts and Practice
Current Gene Therapy Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets How (and Why) to Revive a Dead Enzyme: The Power of Chemical Rescue
Current Chemical Biology Lymphatic Delivery of Anti-HIV Drug Nanoparticles
Recent Patents on Nanotechnology Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Current Cancer Therapy Reviews Bacteria and Bacterial Toxins as Therapeutic Agents for Solid Tumors
Current Cancer Drug Targets Leukotriene A4 Hydrolase as a Target for Cancer Prevention and Therapy
Current Cancer Drug Targets Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine The Design of Drug Candidate Molecules as Selective Inhibitors of Therapeutically Relevant Protein Kinases
Current Medicinal Chemistry Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell
Current Pharmaceutical Biotechnology Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy
Current Drug Targets Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma
Current Drug Targets Lectins in Human Cancer: Both a Devil and an Angel?
Current Protein & Peptide Science Separation of Ginseng Active Ingredients and their Roles in Cancer Metastasis Supplementary Therapy
Current Drug Metabolism Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Biosynthetic and Metabolic Alterations in Cancer Growth
Current Angiogenesis (Discontinued) Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
Current Pharmaceutical Design Linkage of Stress with Neuromuscular Disorders
CNS & Neurological Disorders - Drug Targets Double Strand Break Repair Activities of p53 as Potential Tumor Suppressor Function Counteracting Mammary Tumor Development
Current Women`s Health Reviews BST-2 Expression in Human Hepatocytes is Inducible by All Three Types of Interferons and Restricts Production of Hepatitis C Virus
Current Molecular Medicine